↓ Skip to main content

Dove Medical Press

Article Metrics

A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients

Overview of attention for article published in Drug Design, Development and Therapy, November 2010
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (72nd percentile)
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

patent
7 patents

Citations

dimensions_citation
47 Dimensions

Readers on

mendeley
44 Mendeley
Title
A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients
Published in
Drug Design, Development and Therapy, November 2010
DOI 10.2147/dddt.s14071
Pubmed ID
Authors

MacDonald, Mark Kowalski, Jocelyn Entwistle, Jeannick Cizeau, Demi Niforos, Shauna Loewen, Wendy Chapman

Mendeley readers

The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
France 1 2%
Austria 1 2%
Unknown 42 95%

Demographic breakdown

Readers by professional status Count As %
Researcher 12 27%
Student > Master 6 14%
Student > Ph. D. Student 5 11%
Other 4 9%
Professor > Associate Professor 3 7%
Other 8 18%
Unknown 6 14%
Readers by discipline Count As %
Medicine and Dentistry 17 39%
Agricultural and Biological Sciences 7 16%
Biochemistry, Genetics and Molecular Biology 5 11%
Pharmacology, Toxicology and Pharmaceutical Science 3 7%
Nursing and Health Professions 2 5%
Other 3 7%
Unknown 7 16%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 December 2020.
All research outputs
#3,385,001
of 16,956,273 outputs
Outputs from Drug Design, Development and Therapy
#188
of 1,668 outputs
Outputs of similar age
#78,856
of 285,126 outputs
Outputs of similar age from Drug Design, Development and Therapy
#4
of 27 outputs
Altmetric has tracked 16,956,273 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,668 research outputs from this source. They receive a mean Attention Score of 5.0. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 285,126 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.